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Eff ect of nicotine patches in pregnancy on infant and 
maternal outcomes at 2 years: follow-up from the 
randomised, double-blind, placebo-controlled SNAP trial
Sue Cooper, Jaspal Taggar, Sarah Lewis, Neil Marlow, Anne Dickinson, Rachel Whitemore, Tim Coleman, for the Smoking, Nicotine and Pregnancy 
(SNAP) Trial Team*
Summary
Background The SNAP (Smoking and Nicotine in Pregnancy) trial compared nicotine replacement therapy (NRT) 
patches with placebo in pregnant smokers; although NRT doubled cessation rates in the ﬁ rst 4 weeks, by delivery no 
diﬀ erences in maternal smoking or birth outcomes were noted. As a result, NRT used in standard doses during 
pregnancy is considered ineﬀ ective for smoking cessation. Subsequent eﬀ ects of NRT on the children of treated 
mothers are unknown because no trials have investigated the eﬀ ect of gestational NRT use beyond birth. To assess 
whether NRT use in pregnancy might cause harm to infants, we aimed to compare eﬀ ects of NRT and placebo on 
infant development 2 years after delivery.
Methods 1050 pregnant smokers aged 16–45 years, at 12–24 weeks’ gestation, and smoking at least ﬁ ve cigarettes per 
day were recruited from seven hospitals in England between May 1, 2007, and Feb 26, 2010, and followed up until 
their infants were 2 years old. Participants were randomly assigned (1:1) via a computer-generated pseudorandom 
code with permuted blocks of randomly varying size to receive 8-week courses of NRT patches (15 mg/16 h) (n=521) 
or matched placebo (n=529); both groups received behavioural smoking cessation support. Randomisation was 
stratiﬁ ed by site with participants, health-care professionals, and research staﬀ  masked to treatment allocation. The 
primary results for participants and infants at delivery were published in 2012; we present results from the trial 
cohort 2 years after birth. After delivery, questionnaires were posted to participants and, if there was no response, to 
family physicians. The primary outcome at 2 years was infants’ survival without developmental impairment (ie, no 
disability or problems with behaviour or development). Treatment groups were compared on an intention-to-treat 
basis. The trial is registered with Controlled-Trials.com, number ISRCTN07249128.
Findings Questionnaires were returned at 2 years for 891 (88%) of 1010 live singleton births (445 of (88%) 503 given 
NRT and 446 (88%) of 507 given placebo). Because of missing data, developmental outcomes, including four infant 
deaths, were documented for 888 of (88%) 1010 singleton infants; 445 (88%) of 503 infants in NRT group and 443 
(87%) of 507 infants in placebo. In the NRT group, 323 (73%) of 445 infants had no impairment compared with 290 
(65%) of 443 infants in the placebo group (odds ratio [OR] 1·40, 95% CI 1·05–1·86, p=0·023). At 2 years, 15 (3%) of 
521 mothers in the NRT group and nine (2%) of 529 mothers in the placebo groups self-reported prolonged smoking 
abstinence since a quit date set in pregnancy (OR 1·71, 95% CI 0·74–3·94, p=0·20). Adverse events were not collected 
after delivery, but previously reported adverse pregnancy and birth outcomes were similar in the two groups.
Interpretation Infants born to women who used NRT for smoking cessation in pregnancy were more likely to have 
unimpaired development. NRT had no eﬀ ect on prolonged abstinence from smoking but did cause a temporary 
doubling of smoking cessation shortly after randomisation during pregnancy, which could explain ﬁ ndings. If 
ﬁ ndings are conﬁ rmed by subsequent research, this has potential implications for the management of smoking in 
pregnancy.
Funding National Institute for Health Research Health Technology Assessment Programme.
Copyright © Cooper et al. Open Access article distributed under the terms of CC BY.
Introduction
Smoking in pregnancy is the biggest preventable cause 
of death and illness in women and infants and is 
associated with adverse pregnancy and birth outcomes.1,2 
Despite being an international public health problem, 
and although the prevalence of smoking in pregnancy is 
generally falling in high-income countries,3–6 rates are 
rising in many low-income settings7 and are expected to 
substantially increase the future attributable global 
disease burden.8 Additionally, rates of smoking are 
higher, and declines have often been smaller, in mothers 
who are younger or have lower socioeconomic status.3–5,9 
Smoking in pregnancy might aﬀ ect infant development 
and is associated with behavioural problems, attention 
deﬁ cit disorder,10,11 and reduced academic attainment in 
children.10
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Nicotine replacement therapy (NRT) helps non-
pregnant smokers to stop,12 but although evidence 
suggests that it might help pregnant smokers to achieve 
short-term abstinence,13 compliance with NRT is 
generally poor and by delivery there is no longer any 
evidence for eﬀ ectiveness.14 Previously, we reported 
smoking cessation outcomes from a large trial investi-
gating the eﬃ  cacy of 15 mg/16 h NRT patches used in 
pregnancy (the Smoking and Nicotine in Pregnancy 
[SNAP] trial).13 We reported that NRT had no eﬀ ect on 
validated abstinence from smoking at delivery, although 
validated cessation rates at 1 month after randomisation 
were twice as high in the NRT group; no safety issues 
were identiﬁ ed, with adverse pregnancy and birth 
outcomes similar in the two groups.13
To our knowledge, no trials have investigated the 
eﬀ ect of NRT on outcomes for children beyond delivery; 
thus we designed our study also to assess this. Nicotine 
is potentially fetotoxic.15 One theory is that nicotine from 
either smoking or NRT might stimulate CNS nicotinic 
receptors at inappropriate times during development 
and, consistent with this, nicotine given to pregnant 
rats has a negative eﬀ ect on neurogenesis and 
synaptogenesis in the fetal CNS.15 Therefore, observed 
associations between parental smoking and adverse 
infant develop ment could be plausible,10,11 and might be 
caused by nicotine inhalation from cigarette smoke. As 
a result, NRT might beneﬁ t the fetus and child by 
reducing exposure to smoking at crucial times for 
embryogenesis and infant neural development, but it 
may also cause harm through the negative eﬀ ects of 
direct activation of nicotinic cholinergic receptors in the 
developing CNS. To assess whether NRT patches use by 
pregnant smokers who are trying to quit might be 
harmful, we compared health outcomes at 2 years 
between infants born in placebo group and active group 
from the SNAP trial.
Methods
Study design and participants
SNAP was a multicentre, double-blind, randomised, 
placebo-controlled, parallel-group trial that recruited 
1050 pregnant smokers from seven hospital antenatal 
clinics in England between May 1, 2007, and Feb 26, 
2010; we have previously reported the full methods and 
outcomes at delivery.13 Brieﬂ y, participants were aged 
16–45 years, 12–24 weeks’ gestation, smoked 10 or more 
cigarettes daily before pregnancy, and were smoking 
ﬁ ve or more cigarettes per day at trial enrolment, with 
an exhaled carbon monoxide (CO) reading of at least 
8 ppm. Research midwives obtained written consent, 
collected baseline data, and delivered behavioural 
cessation support to all participants. The research 
midwives then entered eligibility criteria onto a secure 
online database.
The study was approved by Oxfordshire Research 
Ethics Committee A, and all participants gave written 
informed consent, including access to medical records 
for maintaining contact and for following up theirs and 
their child’s health status.
Randomisation and masking
Participants were randomly assigned (1:1) to receive up 
to 8-weeks treatment with NRT (15 mg/16 h transdermal 
patches) or identically packaged and visually matched 
placebo patches (all patches manufactured by and 
purchased at market rate from United Pharmaceuticals, 
Amman, Jordan), issued as two 4-week supplies (521 for 
NRT group, 529 for placebo group). Participants were 
instructed to start using these patches on their quit date, 
to remove them at night, and to only use the patches if 
they were not smoking. Participants were issued with 
the second 4-week supply of patches if they reported not 
smoking one month after their quit date, and this was 
validated with a CO reading less than 8 ppm.
Randomisation was stratiﬁ ed by site, and used a 
computer-generated pseudorandom code with permuted 
blocks of randomly varying size, created by Nottingham 
Clinical Trials Unit. All participants, site pharmacists, and 
research staﬀ  were masked to treatment allocation. 
Additionally, during the 2-year follow-up period after 
ascertainment of primary outcome at delivery, partici-
pants, health-care professionals, and all staﬀ  involved in 
collecting, entering, and classifying follow-up data 
remained masked. Data cleaning and preparatory work 
were done masked to treatment allocation, and all analyses 
at delivery were done masked to study group allocation, 
with codes broken after these were completed. However, 
analysis of the follow-up data was not possible in a 
completely blind manner, because the unblinded data 
from the primary trial was already available. We did not 
evaluate the success of masking for participants or 
research staﬀ .
Procedures
Participants’ smoking status was assessed 1 month after 
randomisation and at delivery, with self-reported non-
smoking status validated by CO concentration, salivary 
cotinine (cotinine is the primary metabolite of nicotine) 
concentration, or both; those participants who had CO 
validated cessation at 1 month (<8 ppm) could receive a 
further 4-week supply of patches. To estimate treatment 
adherence, participants were asked how many study 
patches they had used at 1 month, 2 months (if issued 
with a second 4-week supply), and delivery, and if they 
had used any non-trial NRT.
Safety was assessed by collection of adverse pregnancy 
and birth outcomes from participants and medical notes.
Of 1050 pregnancies, 1034 known live births (1010 
singletons, 24 twins), ﬁ ve miscarriages, seven stillbirths, 
one termination, one missed abortion, and 14 
pregnancies with unknown birth outcomes were noted.13 
Participants with known live infants were posted 
questionnaires at 6, 12, and 24 months after childbirth. 
For more details on how items 
were mapped, see the Statistical 
Analysis Plan at http://eprints.
nottingham.ac.uk/3283/ 
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We did not send questionnaires where participants had 
withdrawn consent, when birth outcomes were 
unknown, or infants who had died either during 
pregnancy or after birth. At each timepoint, we sent one 
postal reminder and attempted telephone completion if 
necessary. To maintain contact, we sent greetings cards 
after childbirth, at Christmas, and on infant’s birthdays, 
including postcards to inform us of address changes. 
We incentivised the return of completed questionnaires 
with a cotton bag at 1 year and a £5 shopping voucher at 
2 years; we also held colouring competitions for 2-year-
olds, oﬀ ering £50 shopping voucher prizes. At 2 years, 
we sent a postal questionnaire to non-respondents’ 
family physicians (Health Professional Questionnaire 
[HPQ]).
At 6, 12, and 24 months, participant questionnaires 
asked about maternal smoking behaviour and infants’ 
respiratory problems. Information about hospital 
admissions (at all timepoints), feeding method 
(6 months and 12 months), and EuroQol (EQ-5D; 
6 months)16 were also collected, but are not reported 
here. The 24-month participant questionnaire (PQ2) 
included ﬁ ve domains of the Ages and Stages 
Questionnaire 3rd edition (ASQ-3)17 (communication, 
gross motor, ﬁ ne motor, problem solving, and personal-
social development); with per mission, wording was 
slightly anglicised. Seven additional PQ2 items (six from 
the ASQ-3) investigated general and speciﬁ c parental 
concerns about infant development. The HPQ, derived 
from a questionnaire used in a similar study,18 was 
designed for completion with medical or health visitor 
records; items were consistent with PQ2, and hence 
ASQ-3, and aimed to measure children’s disability and 
health (questionnaires can be requested from 
corresponding author).19–21
Participants’ Index of Multiple Deprivation (IMD) 
scores were attributed by linkage of postal codes with 
routine English Local Government data;22 a higher score 
indicates more deprivation.
Outcomes
All of the outcomes were binary—ie, participants or 
infants were deﬁ ned as either having the outcome or not.
PQ2 and HPQ responses were combined to derive the 
primary 2-year outcome, which was survival with no 
impairment. This was survival without either of two 
prespeciﬁ ed developmental outcomes; developmental 
and behavioural problems or disability. Details of how 
PQ2 and HPQ items were mapped to these outcomes 
can be found online in the Statistical Analysis Plan. 
Because high rates of disability or developmental 
1050 participants and delivery outcomes previously reported
1036 participants eligible for infant follow-up
1010 singleton livebirth pregnancies
503 nicotine replacement therapy
3 withdrawals
1 withdrew consent
1 postnatal infant death
1 infant taken into care
4 withdrawals
1 withdrew consent
2 postnatal infant death
1 infant taken into care
500 (99%) participant questionnaires
sent at 6 months
334 participant questionnaires 
returned at 6 months
126 (25%) postal
208 (42%) telephone
5 withdrawals
4 withdrew consent
1 postnatal infant death
496 (99%) participant 
questionnaires sent at 1 year
288 participant questionnaires 
returned at 1 year
137 (27%) postal
151 (30%) telephone
2 withdrawals
1 withdrew consent
1 lost to follow-up
493 (98%) PQ2 sent at 2 years
301 PQ2 returned at 2 years
156 (31%) postal
145 (29%) telephone
205 (41%) HPQ sent at 2 years
156 (31%) HPQ returned at 2 years*
48 withdrawals
4 withdrew consent
0 infants adopted
1 lost to follow-up
43 no questionnaire 
completed
445 (88%) PQ2 or HPQ returned at 2 years*
503 (99%) participant questionnaires 
sent at 6 months
331 participant questionnaires 
returned at 6 months
118 (23%) postal
213 (42%) telephone
4 withdrawals
4 withdrew consent
0 postnatal infant death
498 (98%) participant 
questionnaires sent at 1 year
295 participant questionnaires 
returned at 1 year
134 (26%) postal
161 (32%) telephone
2 withdrawals
2 withdrew consent
0 lost to follow-up
497 (98%) PQ2 sent at 2 years
301 PQ2 returned at 2 years
148 (23%) postal
153 (30%) telephone
217 (43%) HPQ sent at 2 years
159 (31%) HPQ returned at 2 years*
51 withdrawals
1 withdrew consent
1 infants adopted
3 lost to follow-up
46 no questionnaire 
completed
446 (88%) PQ2 or HPQ returned at 2 years*
507 placebo
1010 included in ITT 
analyses for infant 
outcomes
12 twin pregnancies
  4 lost to follow-up
10 withdrew consent
14 fetal deaths
Figure: Derivation of the 1010 live singleton births from 1036 pregnancies 
and completeness of infants’ follow-up to 2 years
ITT=intention to treat. PQ2=24-month participant questionnaire. HPQ=health 
professional questionnaire. *26 HPQs were returned in participants who had 
already returned a PQ2 (12 for NRT, 14 for placebo) and these were not included 
in subsequent analyses.
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problems were not expected, combination of outcomes 
provided a clinically meaning ful measure of harm, with 
increased study power for detection of harm from NRT, 
and reduced problems arising from multiple testing. 
Appendix pp 5–6 provides separate results for each of the 
ASQ domains. For cases where both PQ2 and HPQ were 
returned, only PQ2 data were used.
Details of how the absence, presence, or severity of 
impairment was determined from HPQ or PQ2 
responses can be found online in the Statistical Analysis 
Plan. In brief, with the PQ2, infants were deemed to 
have survived with no impairment if scores, derived 
with standard methods for the ﬁ ve ASQ-3 domains, 
were above accepted thresholds indicating normal 
development17 and responses to other, non-domain, 
ASQ-3 items also indicated no problems. For children 
with HPQ returns only, this criterion was met if no 
responses indicated developmental problems. In cases 
for which scores and other responses indicated 
potential impairments, two further mutually-exclusive 
categories were allocated: deﬁ nite and suspected 
develop mental impairment. Infants were classiﬁ ed as 
having deﬁ nite impairment when their ASQ-3 scores 
were at or below the published cut-point in any of the 
domains, or the HPQ responses indicated severe 
disability or developmental delay. Suspected 
impairment was used for cases in which one or more of 
the ASQ-3 scores fell within the questionnaire’s 
borderline range, or if other responses from either the 
PQ2 or HPQ were judged by a clinical member of the 
research team to potentially indicate developmental 
impairment or disability. Deter mination of impairment 
category by this clinician was  done masked to treatment 
allocation.
Infants were classed as having a respiratory problem 
when indicated by any item on either the PQ2 or HPQ. 
Similar to developmental problems, responses were 
combined to avoid multiple testing and to maximise 
power, but individual results are provided in appendix 
pp 7–8.
At all points, participants reported whether they had 
smoked in the last week, and if they had abstained from 
smoking since delivery, with allowance for smoking on 
up to ﬁ ve occasions.23 Prolonged abstinence from 
smoking since the quit date set during pregnancy was 
deﬁ ned as validated abstinence at delivery, plus reported 
abstinence since delivery at every follow up.
Statistical analysis
Sample size for the trial was determined for the 
previously reported primary outcome of smoking 
cessation rate at delivery.13 Within those participants 
available at follow-up, baseline maternal characteristics 
and birth outcomes were compared between trial groups; 
the same characteristics were also compared in those 
who had outcomes determined by PQ2, HPQ, or who 
were lost to follow-up at 2 years. Statistical analyses were 
done with Stata/SE version 11.2 (StataCorp LP, College 
Station, TX, USA).
NRT Placebo
Maternal characteristics at study enrolment; n=448 for NRT, n=452 for placebo*
Age (years) 26·5 (6·2) 26·3 (6·1)
Number of cigarettes smoked daily before pregnancy 20 (15–20) 20 (15–20)
Number of cigarettes smoked daily at baseline 13 (10–20) 15 (10-20)
Gestational age at baseline (weeks) 16·2 (3·5) 16·3 (3·5)
Ethnic origin
White British 434 (97%) 442 (98%)
Other 14 (3%) 10 (2%)
Age when left full time education (years) 16·2 (1·4) 16·3 (1·7)
Missing data (n) 5 8
Index of multiple deprivation 32·1 (16·7) 32·4 (16·9)
Missing data (n) 13 9
Parity
0–1 306 (68%) 311 (69%)
2–3 111 (25%) 121 (27%)
≥4   31 (7%) 20 (4%)
Salivary cotinine at baseline (ng/mL) 123·7 (80·2–185·4) 120·9 (75·6–175·9)
Missing data (n) 35 33
Time from waking to fi rst cigarette (min)
0–15 245 (55%) 243 (54%)
16–60 169 (38%) 168 (37%)
>60 34 (8%) 34 (8%)
Women with partner who smokes 306 (68%) 306 (68%)
Missing data (n, %) 34 (8%) 38 (8%)
Height (cm) 162·9 (6·8) 163·1 (6·4)
Missing data (n) 12 13
Weight (kg) 71·2 (17·8) 72·3 (17·1)
Missing data (n) 8 8
Previous preterm birth 38 (8%) 42 (9%) 
Length of fi rst behavioural support session 
<30 min 66 (15%) 67 (15%)
31–60 min 376 (84%) 371 (82%)
>60 min 6 (1%) 14 (3%)
Use of NRT earlier in pregnancy 19 (4%) 23 (5%)
Maternal smoking outcomes at delivery; n=448 for NRT, n=452 for placebo*
Met primary smoking cessation outcome 46 (10%) 37 (8%)
Infant birth outcomes at delivery; n= 445 for NRT, n=446 for placebo†
Birthweight, unadjusted (kg) 3·2 (0·6) 3·2 (0·6)
Gestational age (weeks) 39·5 (2·1) 39·5 (2·2)
Preterm birth 36 (8%) 40 (9%)
Low birthweight (<2·5 kg) 49 (11%) 37 (8%)
Neonatal intensive-care unit admission 29 (7%) 32 (7%)
Apgar score at 5 min <7 12 (3%) 13 (3%)
Congenital abnormalities 7 (2%) 12 (3%)
Infant on ventilator >24 h 8 (2%) 10 (2%)
Assisted vaginal delivery 33 (7%) 37 (8%)
Delivery by caesarean section 90 (20%) 69 (15%)
Data are n (%), median (range), or mean (SD). NRT=nicotine replacement therapy. *All pregnancies (ie, includes twins). 
†Singleton pregnancies only.
Table 1: Comparison of maternal characteristics and birth outcomes for participants who provided data at 2 years
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Separate multivariable analyses were done for presence 
or absence of every outcome, including the primary 
outcome (survival with no impairment), and for 
secondary outcomes (deﬁ nite impairment, respiratory 
problems, and maternal smoking behaviour). For 2-year 
outcomes, treatment groups were compared on an 
intention-to-treat basis. Infant outcomes were only 
compared for pregnancies that were known to have 
resulted in live births. Pregnancies that ended in fetal 
death before birth (eg, miscarriage, stillbirth, or elective 
termination), and those for which the pregnancy 
outcome was unknown did not contribute to analyses, 
but postnatal infant deaths were included in the 
denominator for developmental outcomes. We did the 
primary analysis within singleton births, because non-
independent, multiple births might have worse birth 
outcomes than singletons. We then compared results 
with those obtained after multiple imputation to deal 
with missing values. Multiple imputation was done with 
mi commands in Stata, including complete baseline 
variables, smoking status at delivery, and treatment 
allocation in the imputation model (20 imputations). 
Treatment eﬀ ects were estimated from imputed datasets 
with logistic regression adjusted for centre as the 
stratiﬁ cation factor. We then did two further analyses; a 
complete case analysis including multiple births allowing 
for clustering,24 and a further full population analysis 
with parent PQ2 questionnaires only.
In a prespeciﬁ ed secondary analysis, we used logistic 
regression to explore the dose–response relation between 
self-reported adherence with nicotine patches13 and, as a 
dependent variable, infants’ survival without impairment. 
For this analysis, three categories were created: zero 
adherence (ie, allocated placebo patch or reported zero 
nicotine patches used) and, for participants reporting use 
of at least one nicotine patch, two categories representing 
above and below the median reported adherence of 
10 nicotine patches (ie, 1–10 and 11–56 days adherence).
Smoking outcomes for the treatment groups at 6, 12, 
and 24 months were compared on an intention-to-treat 
basis, with non-respondents assumed to smoke. Logistic 
regression, adjusted for centre, provided odds ratios for 
the treatment eﬀ ect, and a sensitivity analysis adjusted 
for baseline salivary cotinine, partner’s smoking status, 
and age at ﬁ nishing education was done. Finally, a 
sensitivity analysis investigated the eﬀ ect on ﬁ ndings of 
alternatives to the assumption that those with missing 
data were smokers.25
The trial is registered with Controlled-Trials.com, 
number ISRCTN07249128.
Role of the funding source
The funders of this study had no role in the study design, 
data collection, data analysis, data interpretation, or 
writing of the report. SC, JT, SL, and TC had full access to 
the data in the study. SC and TC had the ﬁ nal 
responsibility for the decision to submit for publication.
Results
Follow-up was completed by Dec 14, 2012. The ﬁ gure 
shows the derivation of the 1010 live singleton births 
For more details on how 
impairment was determined, see 
the Statistical Analysis Plan at 
http://eprints.nottingham.ac.
uk/3283/
Followed up
(PQ2; n=606)
Followed up
(HPQ; n=294)*
Not followed up
(n=150)†
Maternal characteristics at enrolment/randomisation (all pregnancies)
Age (years) 26·9 (6·3) 25·5 (5·6) 25·7 (6·3)
Cigarettes smoked daily before pregnancy 20 (15–20) 20 (15–20) 20 (15–20)
Cigarettes smoked daily at baseline 15 (10–20) 15 (10–18) 12 (10–15)
Gestational age at baseline (weeks) 16·2 (3·5) 16·4 (3·5) 16·2 (3·6)
Ethnic origin
White British 588 (97%) 288 (98%) 142 (95%)
Other 18 (3%) 6 (2%) 8 (5%)
Age left full time education (years) 16·3 (1·7) 16·2 (1·3) 16·3 (1·5)
Index of Multiple Deprivation 32·3 (17·1) 32·2 (16·2) 36·8 (16·0)
Parity
0–1 424 (70%) 193 (66%) 102 (68%)
2–3 144 (24%) 88 (30%) 39 (26%)
≥4   38 (6%) 13 (4%) 9 (6%)
Salivary concentration level at baseline (ng/mL) 119·1 (72·1–
179·5
131·6 (88·7–
184·7)
119·1 (80·0–
161·3)
Time from waking to fi rst cigarette
0–15 min 329 (54%) 159 (54%) 78 (52%)
16–60 min 231 (38%) 106 (36%) 60 (40%)
>60 min 46 (8%) 29 (10%) 12 (8%)
Women with partner who smokes 408 (67%) 204 (69%) 104 (69%)
Height (cm) 162·9 (6·8) 163·2 (6·3) 163·7 (7·0)
Weight (kg) 72·4 (16·6) 70·5 (19·1) 71·0 (18·9)
Previous preterm birth 47 (8%) 33 (11%) 12 (8%)
Length of fi rst behavioural support session
<30 min 87 (14%) 46 (16%) 32 (21%)
31–60 min 505 (83%) 242 (82%) 114 (76%)
>60 min 14 (2%) 6 (2%) 4 (3%)
Use of NRT earlier in pregnancy 33 (5%) 9 (3%) 5 (3%)
Maternal smoking at delivery (all pregnancies)
Met primary smoking cessation outcome 66 (11%) 17 (6%) 6 (4%)
Infant birth outcomes (singleton pregnancies; n=602 for PQ2, n=289* for HPQ, n=119 for not followed up)  
Birthweight, unadjusted (kg) 3·2 (0·58) 3·1 (0·62) 3·2 (0·60)
Gestational age (weeks) 39·5 (2·1) 39·4 (2·3) 39·6 (2·1)
Preterm birth 46 (8%) 30 (10%) 9 (8%)
Low birthweight (<2·5 kg) 46 (8%) 40 (14%) 13 (11%)
NICU admission 39 (6%) 22 (8%) 7 (6%)
Apgar score at 5 min <7 13 (2%) 12 (4%) 9 (8%)
Congenital abnormalities 8 (1%) 11 (4%) 3 (3%)
Infant on ventilator >24 h 11 (2%) 7 (2%) 3 (3%)
Assisted vaginal delivery 51 (8%) 19 (7%) 11 (9%)
Delivery by caesarean section 118 (20%) 41 (14%) 25 (21%)
Data are n (%), median (range), or mean (SD). PQ2=24-month participant questionnaire. HPQ=health professional 
questionnaire (also at 24 months). NRT=nicotine replacement therapy. *26 participants who provided both HPQ and 
PQ2 data were excluded from this analysis (n=12 for NRT, n=14 for placebo, all singleton pregnancies). †Includes 
participants who experienced fetal or infant death (n=18), whose pregnancy outcome was unknown (n=14), and those 
who withdrew, were lost to follow-up or did not return questionnaires at 24 months (n=118).
Table 2: Maternal and infant characteristics—comparison of participants and singleton infants for whom 
outcome data was and was not available at 2 years 
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from 1036 pregnancies and completeness of infants’ 
follow-up to 2 years (appendix p 2). Of singleton infants, 
891 (88%) participants returned a PQ2 or HPQ; 445 
(88%) of 503 infants given NRT and 446 (88%) of 507 
infants given placebo. 26 (3%) of 990 participants were 
late returning their PQ2, and an HPQ had also been sent 
and returned; the PQ2 was our primary source of data 
and so these 26 HPQs were not analysed. Because of 
missing data, development outcomes were only 
attributable for 443 infants in the NRT group and 441 
infants in the placebo group (including four postnatal 
infant deaths [two for NRT, two for placebo]) and 
respiratory outcomes for 444 infants in the NRT group 
and 444 infants in the placebo group.
Of participants and singleton infants with 2-year 
outcome data, baseline characteristics and birth 
outcomes in the NRT and placebo groups were generally 
similar (table 1). These comparison groups at 2 years also 
had similar characteristics to those previously reported 
in the full trial cohort.13 At 2 years, as seen at delivery, 
more births by caesarean occurred in the NRT group 
than in the placebo group (table 1). The proportion of 
mothers at 2 years who had had validated abstinence 
from smoking at delivery (table 1) was again comparable 
to those in the full cohort (49 [9%] of 521 mothers in the 
NRT group and 40 [8%] of 529 in the placebo group).13
Table 2 shows a comparison of characteristics between 
participants who returned PQ2s, those for whom HPQs 
were completed, and those lost to follow-up. The mean 
IMD score was higher in those participants who were not 
followed up compared with that for PQ2 and for HPQ 
(table 2), but most diﬀ erences between the groups’ baseline 
characteristics or birth outcomes were minor. Breast-
feeding rates reported at 6 months were very similar in the 
two groups; 133 (40%) of 330 respondents in the NRT 
group reported breastfeeding exclusively immediately after 
childbirth compared with 126 (38%) of 333 in the placebo 
group, and by 6 months these rates had fallen to 14 (4%) 
participants for NRT and 10 (3%) for placebo.
Table 3 shows infant developmental and respiratory 
outcomes by treatment groups for all those participants 
with known outcomes, including four postnatal deaths. 
Infants born to women receiving NRT were signiﬁ cantly 
more likely to have survived with no impairment than 
those receiving placebo (table 3). In the ITT analysis with 
multiple imputation, the primary outcome was signiﬁ -
cantly more common in the NRT than in the placebo 
group (table 3). Findings from complete case analyses of 
singleton pregnancies only and adjusted for clustering by 
twin pregnancies (table 3), and from similar analyses of 
just PQ2 responses (excluding postnatal deaths) 
(appendix p 3), were very similar. For example, in the 
complete case analysis of PQ2 responses for singleton 
infants, the diﬀ erence in primary outcomes between 
groups was comparable to that in the main analysis 
(OR 1·52, 95% CI 1·09–2·11, p=0·0124; appendix p 3).
Analyses of individual ASQ-3 domains showed eﬀ ects of 
similar size and direction, although only diﬀ erences in 
the personal social domain reached statistical signiﬁ cance.
Findings from comparison of scores on individual 
domains were: ﬁ ne motor skills (OR 1·30, 95% CI 
0·82–2·08, p=0·27), gross motor skills (1·40, 0·87–2·22, 
NRT Placebo Complete case analysis 
(singleton pregnancies)**
Complete case analyses 
(adjusted for clustering by 
twin pregnancies)††‡‡
Multiple imputation ITT 
analyses (singleton births; 
n=1010)
OR (95% CI) p value OR (95% CI) p value OR (95% CI) p value
Number of respondents* 445 446
Number with development outcomes documented† 443 441 .. .. .. .. .. ...
Number of infant deaths (after delivery) 2 2 .. .. .. .. .. ..
Number with known developmental outcomes 445 443 .. .. .. .. .. ..
Survival with no impairment‡ 323/445 (73%) 290/443 (65%) 1·41 (1·05–1·87) 0·0202 1·43 (1·08–1·91) 0·013 1·40 (1·05–1·86) 0·023
Defi nite developmental impairment§ 48/445 (11%) 64/443 (14%) 0·71 (0·48–1·06) 0·09 0·73 (0·49–1·09) 0·13 0·71 (0·47–1·09) 0·12
Suspected development impairment (%)¶ 72/445 (16%) 87/443 (20%) .. .. .. .. .. ..
Number with respiratory outcomes documented† 444 444 .. .. .. .. .. ..
Respiratory problems|| 132/444 (30%) 111/444 (25%) 1·28 (0·95–1·73) 0·10 1·32 (0·98–1·77) 0·07 1·30 (0·97–1·74) 0·08
Data are n or n (%). NRT=nicotine replacement therapy. ITT=intention to treat. OR=odds ratio. *Participants with singleton livebirths with a response to either questionnaire (24-month participant questionnaire 
[PQ2] or health professional questionnaire [HPQ]) at 2-year follow-up. †Because of missing data, developmental outcomes were not documented for seven participants (n=2 for HPQ in NRT group; n=1 for PQ2, 
n=4 for HPQ in placebo). Because of missing data, respiratory outcomes could not be determined for three participants (n=1 for HPQ in NRT group; n=1 for PQ2, n=1 for HPQ in placebo). ‡Score above borderline 
score in ASQ-3 for all domains, and no problems reported in additional sections of ASQ-3 (ie, any hearing, talking, understanding, neuromotor or vision problems). §ASQ-3 score equal to or below cutpoint in ≥1 
domain, HPQ indicates severe disability and/or severe developmental delay. ¶ASQ-3 borderline score in ≥1 domain, but no scores equal to or below cut-point, and/or judged to have mild/moderate or possible 
impairment, disability or development delay from the additional questions on the PQ2 and/or HPQ including problems with hearing, speech, neuromotor, vision, behaviour, or feeding problems. ||Any report of 
respiratory symptoms, asthma diagnosis, asthma medications, or admissions to hospital for respiratory problems at 2-year follow-up; this denominator does not include postnatal infant deaths because it is not 
possible to attribute these infants with a respiratory outcome. **Because of missing data, denominators were diff erent for each outcome; total infants with known developmental outcomes (including postnatal 
infant deaths) was 888 (445 plus 443); total infants with known respiratory outcomes (excluding postnatal infant deaths) was 888 (444 plus 444). ††Infants from nine twin pregnancies returned a PQ2 or HPQ 
(n=6 for NRT, n=12 for placebo). ‡‡Because of missing data, denominators were diff erent for each outcome: total infants (including twins) with known developmental outcomes (including postnatal deaths) was 
906 (451 plus 455); total infants (including twins) with known respiratory outcomes (excluding postnatal infant deaths) was 906 (450 plus 456). 
Table 3: Infant development and respiratory outcomes at 2 years compared between treatment groups
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p=0·15), communication (1·21, 0·75–1·96, p=0·43), 
problem solving (1·34, 0·90–2·01, p=0·15), personal 
social (1·64, 1·08–2–48, p=0·0184; appendix p 5). The 
results showed a dose–response relation between use of 
NRT patches in pregnancy and infant outcomes at 2 years 
compared with infants born to participants who did not 
use nicotine patches, but we noted no diﬀ erence in 
outcomes of infants born to women who reported using 
between one and 10 NRT patches (appendix p 9). However, 
those infants born to women who reported using between 
11 and 56 NRT patches were more likely to have no 
impairments (OR [adjusted for partner smoking status] 
1·72, 95% CI 1·22–2·57, p=0·004).
Combined respiratory outcomes could be attributed for 
888 of the singleton infants; 444 infants in the NRT 
group and 444 infants in the placebo group; of which 132 
(30%) in the NRT group and 111 (25%) in the placebo 
group reported respiratory problems (table 3); further 
breakdown of respiratory outcomes is shown in appendix 
pp 7–8).
For smoking outcomes, response rates at the three 
timepoints are shown in table 4, and are for all 
1050 randomised women. Response rates were around 
64% at 6 months, falling slightly to 58% at 2 years; these 
are lower than those for the developmental and respiratory 
outcomes as the smoking questions were only included in 
the participant questionnaires. After delivery, abstinence 
from smoking was low, and the relapse rate gradually 
increased (table 4). Slightly more participants reported not 
smoking in the NRT group than placebo at each timepoint, 
but none were signiﬁ cantly diﬀ erent (table 4). By 2 years 
after delivery, 15 (3%) participants allocated NRT and nine 
(2%) allocated placebo remained abstinent (table 4); the 
sensitivity analysis noted that varying the assumptions 
made that those with missing data were all smokers had 
almost no eﬀ ect on this eﬀ ect size.
Additional adverse events were not collected after 
delivery, but previously reported adverse pregnancy and 
birth outcomes were similar in the two groups.13
Discussion
At 2 years of age, infants born to women who had been 
allocated to receive NRT in pregnancy were more likely to 
have survived without developmental impairments than 
those in the placebo group, but no diﬀ erences in the 
frequency of respiratory problems were noted (panel). 
NRT had only minor eﬀ ects on smoking cessation, with 
very low prolonged abstinence rates 2 years after delivery. 
To our knowledge this is the ﬁ rst time a trial has reported 
the eﬀ ect of a smoking cessation intervention in pregnancy 
on infant outcomes beyond delivery, and also the ﬁ rst time 
that maternal smoking rates within trial groups have been 
reported longer than 18 months after childbirth.
Using rigorous methods to maintain contact with 
participants, we achieved high outcome ascertainment 
rates, with low rates of withdrawal and missing data. In 
conjunction with staﬀ  doing the follow-up being masked 
to treatment allocation, this might account for the similar 
baseline characteristics of the two groups and the absence 
of systematic diﬀ erences between those lost to follow-up 
and those included in analyses (tables 1, 2). Multiple 
imputation included complete baseline variables, smoking 
NRT (n=521)* Placebo (n=529)* Adjusted for centre only Adjusted‡
OR (95% CI)† p value OR (95% CI) p value
6 months after delivery
Respondents 335 (64%) 338 (64%) ·· ·· ·· ··
Self-reported prolonged abstinence since delivery§ 57 (11%) 50 (9%) 1·18 (0·79–1·76) 0·43 1·23 (0·81–1·87) 0·33
Self-reported 7 day cessation (%) 56 (11%) 52 (10%) 1·11 (0·74–1·65) 0·62 1·15 (0·76–1·74) 0·50
Prolonged abstinence from smoking between quit date and 6 months after delivery¶ 28 (5%) 17 (3%) 1·71 (0·92–3·17) 0·08 1·84 (0·98–3·46) 0·0547
1 year after delivery
Respondents 288 (55%) 300 (57%) ·· ·· ·· ··
Self-reported prolonged abstinence since delivery§|| 33 (6%) 29 (5%) 1·16 (0·70–1·95) 0·56 1·18 (0·69–2·04) 0·54
Self-reported 7 day cessation|| 55 (11%) 37 (7%) 1·57 (1·01–2·43) 0·0413 1·55 (0·98–2·46) 0·06
Prolonged abstinence from smoking between quit date and 1 year after delivery¶|| 19 (4%) 11 (2%) 1·78 (0·84–3·78) 0·13 2·20 (0·98–4·92) 0·0475
2 years after delivery
Respondents (PQ2 only)** 302 (58%) 304 (57%) ·· ·· ·· ··
Self-reported prolonged abstinence since delivery§ 23 (4%) 21 (4%) 1·11 (0·61–2·04) 0·73 1·03 (0·53–1·98) 0·94
Self-reported 7 day cessation 45 (9%) 43 (8%) 1·06 (0·69–1·65) 0·78 0·98 (0·62–1·56) 0·95
Prolonged abstinence from smoking between quit date and 2 years after delivery¶ 15 (3%) 9 (2%) 1·71 (0·74–3·94) 0·20 1·96 (0·82–4·70) 0·12
Data are n (%), unless otherwise indicated. NRT=nicotine replacement therapy. OR=odds ratio. PQ2=24-month participant questionnaire. *For the smoking outcomes, participants who did not provide data or 
were lost to follow-up are assumed to be smokers and included in the denominator. †Adjusted for centre only (as a stratifi cation factor). ‡Adjusted for centre, salivary cotinine concentration at baseline, partner’s 
smoking status, and age at leaving full time education. §Self-reported prolonged abstinence since delivery in the table suggests the participant smoked less than fi ve times since baby was born. ¶Participant met 
criteria for prolonged abstinence at delivery (ie, positive primary outcome) plus self-reported smoking less than fi ve times since baby was born. ||Cessation information was collected at 1 year, but was not listed 
as an outcome in the protocol. **Smoking status was only ascertained in the PQ2.
Table 4: Maternal smoking outcomes at 6 months, 1 year, and 2 years after delivery
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status at delivery, and treatment allocation in the model 
and so should satisfactorily adjust for the minor 
diﬀ erences in baseline characteristics of respondents such 
as mode of delivery; hence ﬁ ndings from the analyses 
presented are likely to be internally valid.
A medically qualiﬁ ed researcher, masked to treatment 
allocation, manually checked all free-text responses on 
the outcome questionnaires and, if these generated 
uncertainty about either the presence or gravity of 
impairment, this was categorised as suspected, rather 
than deﬁ nite or no impairment. This approach was also 
taken with respiratory item responses. The similar 
pattern of ﬁ ndings across all pre-planned analyses, 
irrespective of data sources used, suggests consistent 
allocation of outcomes.
The ASQ-3, which was the basis of our parent-completed 
questionnaire, is a screening instrument designed to 
accurately identify children with develop mental problems 
and so avoid over-referrals and under-referrals for further 
assessment.17 In a comparable setting, when compared 
with such subsequent assess ments, a similar earlier 
version of the ASQ had a sensitivity of 87·4% (speciﬁ city 
82·3%).32 Although this sensitivity suggests that our 
outcome measure will have had good discrimination, 
some impaired infants will probably not have been 
detected and some non-impaired infants will have been 
wrongly labelled as impaired; face-to-face assessment 
would have been more accurate. However, the masking of 
respondents and outcome assessors make it unlikely that 
trial groups will have had diﬀ erent rates of outcome 
misclassiﬁ cation. Factors that were not measured, such as 
nutrition or environment, could have aﬀ ected childhood 
development; however, this was a large randomised, 
blinded trial that was well-balanced for most characteristics 
that were collected. Developmental impairment is a fairly 
common outcome and, like all studies that use OR for an 
outcome that is not rare, our OR estimates might 
overestimate the risk ratio. Nevertheless, the observed 
diﬀ erence in develop mental outcomes between trial 
groups is likely to be real and meaningful.
We assumed that all participants without smoking 
outcome data were smokers. Results of analyses 
investigating the eﬀ ects of diﬀ erent associations between 
smoking behaviour and being lost to follow up showed that 
alternative assumptions did not change the ﬁ ndings; 
however, because smoking outcomes after delivery were 
not validated, actual prolonged quit rates could be even 
lower. Although we report data for maternal smoking 
status at 6 months, 1 year, and 2 years (table 4), data 
collected did not include cumulative number of cigarettes 
smoked, which would have been useful for assessment of 
whether or not NRT resulted in reduced smoking either 
during use or after its discontinuation. Nevertheless, 
because we note a signiﬁ cant diﬀ erence in validated quit 
rates 1 month after randomisation, which was reported in 
our previous paper (OR 2·10, 95% CI 1·49–2·97),13 we do 
know that those in the NRT group had reduced their 
smoking more than those in the placebo group for at least 
4 weeks during the second trimester—an important period 
in embryo development. Additionally, before 2 years of age, 
most infant exposure to environmental tobacco smoke 
(ETS) is domestic and attributable to parental smoking;33 as 
a result, data for maternal smoking are likely to reﬂ ect 
infants’ exposure to ETS and the design of the study is such 
that any biases in reporting of smoking habits would aﬀ ect 
both groups similarly. Unfortunately, after delivery, we 
collected no further biochemical measures of maternal 
smoking and no biomarkers of tobacco smoke exposure 
were obtained directly from the infants in the study, and so 
we cannot make any deﬁ nitive conclusions about infants’ 
exposure to ETS. Additionally, we acknowledge that 
participant recall or report of smoking might be inaccurate; 
however, there is no reason to believe that this will be 
diﬀ erent between the groups. Also, we did not collect any 
data for alcohol intake during pregnancy, but because other 
baseline characteristics were similar we do not suspect that 
this would have been diﬀ erent between the two groups.
We did not anticipate ﬁ nding better outcomes in the 
infants in the NRT group; however, although less 
Panel: Research in context
Systematic review
When planning this trial, a published Cochrane review was 
consulted.26 This systematic review established that at the 
outset of our trial (Feb 1, 2006), only three randomised 
controlled trials27–29 had investigated the use of nicotine 
replacement therapy (NRT) for smoking cessation in 
pregnancy, with no evidence from these that NRT was 
eff ective to help pregnant women stop smoking. Additionally, 
none of these trials had monitored maternal smoking rates 
after delivery or child outcomes such as respiratory symptoms 
or developmental impairment. More recently, two Cochrane 
reviews, including one authored by some of the SNAP team, 
have collated trials investigating pharmacological14 and 
psychosocial cessation30 interventions in pregnancy, and 
neither includes any studies that report infant outcomes 
beyond delivery. Evidence-based WHO guidance on smoking 
in pregnancy similarly showed no studies of smoking 
cessation during pregnancy that addressed infant outcomes, 
and recommended further research on the safety of 
pharmacotherapeutic cessation drugs.31  
Interpretation
To our knowledge, this is the fi rst time a trial has tested the 
eff ects of a smoking cessation intervention delivered in 
pregnancy on infant outcomes. We showed that NRT used for 
smoking cessation during pregnancy resulted in better infant 
developmental outcomes. These improved outcomes could 
have been caused by reduced maternal smoking during 
pregnancy, even though, overall, NRT was not considered 
eff ective for prolonged cessation. This fi nding should be 
further evaluated through reassessment of the infants of the 
SNAP trial in later childhood. 
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impairment was noted in children of mothers who 
reported greater than median adherence with nicotine 
patches, ﬁ ndings from this analysis should be considered 
exploratory. The observed dose–response relation could 
suggest a real eﬀ ect, attributable to NRT, but equally, 
alternative explanations might exist. For example, this 
analysis does not take into account the fact that people 
who adhere with treatments might diﬀ er (eg, in lifestyle 
and health behaviours) from those who do not, and 
improved infant outcomes might have occurred because 
of diﬀ erences other than the nicotine contained in the 
transdermal patches used in the trial. A direct beneﬁ cial 
eﬀ ect of nicotine on the developing fetus seems unlikely 
because animal studies suggest this might be toxic;15,34 
however, animal studies might not be directly relevant to 
human beings and positive eﬀ ects from nicotine cannot 
be ruled out. Beneﬁ t might also have been mediated 
through reduced maternal smoking, although as the 
limitations noted suggest, this cannot be deﬁ nitively 
proven from our data. Smoking in pregnancy has 
recently been reported to have a dose–response relation 
with conduct problems in oﬀ spring, an association that 
seems independent of either maternal characteristics or 
those of the child-rearing environment, including 
exposure to tobacco smoke after birth.35 Most neurons 
are thought to develop in the ﬁ rst two trimesters of 
pregnancy, with interconnections between these 
becoming organised between 24 weeks and term, 
however further maturation of these connections 
continues during the ﬁ rst 2 years after birth and beyond,36 
and fetal cerebral growth continues into late pregnancy.37 
However, smaller brain volumes are associated with fetal 
exposure to maternal smoking38 and it is feasible that 
normal brain developmental processes were dis-
proportionately aﬀ ected in foetuses in the placebo group. 
Diﬀ erent mechanisms underpin fetal lung development, 
which might explain the absence of eﬀ ect on respiratory 
outcomes. A similar, but smaller, placebo-controlled trial 
by Wisborg and colleagues27 noted lower cotinine con-
centrations in mothers in the NRT group and signiﬁ cantly 
higher birthweight in the NRT group. The trial also 
reported that NRT had no eﬀ ect on abstinence throughout 
pregnancy. Superﬁ cially, these ﬁ ndings could also seem 
to support the notion that NRT might reduce smoking 
enough to improve neonatal outcomes, even in the 
absence of an eﬀ ect on sustained cessation. However, 
because diﬀ erences in cotinine concentrations and 
smoking rates between trial groups in late pregnancy 
were both non-signiﬁ cant, with much missing data for 
cotinine, and because no markers that are speciﬁ c to 
tobacco smoke rather than NRT exposure were collected, 
we prefer not to hypothesise about potential reductions 
in fetal exposure to tobacco smoke in that study. Although 
such reductions remain a possibility, similar birthweight 
diﬀ erences have not been consistently observed across 
other trials of NRT used for smoking cessation in 
pregnancy.14
The hypothesis that the NRT eﬀ ects were mediated 
through reduced smoking is consistent with evidence that 
smoking during pregnancy adversely aﬀ ects human brain 
development.39 Little evidence supports an alternative 
hypothesis that, when compared with smoking in 
pregnancy, nicotine has a directly beneﬁ cial eﬀ ect; however 
both hypotheses require further investigation because 
conﬁ rmation of either has potentially major implications 
for the management of smoking in pregnancy.
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